Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms

Andrew V Schally, T. W. Redding, A. M. Comaru Schally

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

New approaches to the therapy for some endocrine-dependent tumors with analogs of hypothalamic hormones are being developed on the basis of experimental studies in animal models. Analogs of luteinizing hormone-releasing hormones (LH-RH) may open new vistas for the treatment of some hormone-dependent carcinomas. It has been clearly demonstrated that both agonistic and antagonistic analogs of LH-RH can inhibit the growth of rat prostate tumors. A successful treatment of androgen-dependent prostate cancer with agonistic analogs of D-Trp6-LH-RH, D-Ser(Bu(t))6des-Gly-NH210-LH-RH ethylamide, and D-Leu6-des-Gly-NH210-LH-RH ethylamide has been documented in several hundred patients. The data accumulated so far from clinical trials suggest that LH-RH agonists can be used as an effective endocrine therapy for prostate carcinoma, thereby avoiding the side effects of estrogen and the psychologic impact of castration. Experimental animal studies and some clinical trials suggest that LH-RH agonists and/or antagonists might also be useful in the treatment of breast cancer. The results of experiments with various hypothalamic analogs in animal models of chondrosarcomas, osteosarcomas, and other tumors appear to be encouraging, but the potential clinical efficacy of LH-RH analogs in the treatment of human hormone-sensitive cancers other than breast and prostate remains to be investigated. The approach to treatment of hormone-dependent tumors based on analogs of hypothalamic hormones might become a useful addition to conventional methods for cancer therapy.

Original languageEnglish
Pages (from-to)281-289
Number of pages9
JournalCancer Treatment Reports
Volume68
Issue number1
StatePublished - Jan 1 1984
Externally publishedYes

Fingerprint

Gonadotropin-Releasing Hormone
Hormones
Neoplasms
Hypothalamic Hormones
Therapeutics
Prostate
Prostatic Neoplasms
Animal Models
Clinical Trials
Breast Neoplasms
Carcinoma
Chondrosarcoma
Castration
Osteosarcoma
Androgens
Estrogens
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms. / Schally, Andrew V; Redding, T. W.; Comaru Schally, A. M.

In: Cancer Treatment Reports, Vol. 68, No. 1, 01.01.1984, p. 281-289.

Research output: Contribution to journalArticle

@article{b8f62f14cfdb425899390512da7d666c,
title = "Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms",
abstract = "New approaches to the therapy for some endocrine-dependent tumors with analogs of hypothalamic hormones are being developed on the basis of experimental studies in animal models. Analogs of luteinizing hormone-releasing hormones (LH-RH) may open new vistas for the treatment of some hormone-dependent carcinomas. It has been clearly demonstrated that both agonistic and antagonistic analogs of LH-RH can inhibit the growth of rat prostate tumors. A successful treatment of androgen-dependent prostate cancer with agonistic analogs of D-Trp6-LH-RH, D-Ser(Bu(t))6des-Gly-NH210-LH-RH ethylamide, and D-Leu6-des-Gly-NH210-LH-RH ethylamide has been documented in several hundred patients. The data accumulated so far from clinical trials suggest that LH-RH agonists can be used as an effective endocrine therapy for prostate carcinoma, thereby avoiding the side effects of estrogen and the psychologic impact of castration. Experimental animal studies and some clinical trials suggest that LH-RH agonists and/or antagonists might also be useful in the treatment of breast cancer. The results of experiments with various hypothalamic analogs in animal models of chondrosarcomas, osteosarcomas, and other tumors appear to be encouraging, but the potential clinical efficacy of LH-RH analogs in the treatment of human hormone-sensitive cancers other than breast and prostate remains to be investigated. The approach to treatment of hormone-dependent tumors based on analogs of hypothalamic hormones might become a useful addition to conventional methods for cancer therapy.",
author = "Schally, {Andrew V} and Redding, {T. W.} and {Comaru Schally}, {A. M.}",
year = "1984",
month = "1",
day = "1",
language = "English",
volume = "68",
pages = "281--289",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms

AU - Schally, Andrew V

AU - Redding, T. W.

AU - Comaru Schally, A. M.

PY - 1984/1/1

Y1 - 1984/1/1

N2 - New approaches to the therapy for some endocrine-dependent tumors with analogs of hypothalamic hormones are being developed on the basis of experimental studies in animal models. Analogs of luteinizing hormone-releasing hormones (LH-RH) may open new vistas for the treatment of some hormone-dependent carcinomas. It has been clearly demonstrated that both agonistic and antagonistic analogs of LH-RH can inhibit the growth of rat prostate tumors. A successful treatment of androgen-dependent prostate cancer with agonistic analogs of D-Trp6-LH-RH, D-Ser(Bu(t))6des-Gly-NH210-LH-RH ethylamide, and D-Leu6-des-Gly-NH210-LH-RH ethylamide has been documented in several hundred patients. The data accumulated so far from clinical trials suggest that LH-RH agonists can be used as an effective endocrine therapy for prostate carcinoma, thereby avoiding the side effects of estrogen and the psychologic impact of castration. Experimental animal studies and some clinical trials suggest that LH-RH agonists and/or antagonists might also be useful in the treatment of breast cancer. The results of experiments with various hypothalamic analogs in animal models of chondrosarcomas, osteosarcomas, and other tumors appear to be encouraging, but the potential clinical efficacy of LH-RH analogs in the treatment of human hormone-sensitive cancers other than breast and prostate remains to be investigated. The approach to treatment of hormone-dependent tumors based on analogs of hypothalamic hormones might become a useful addition to conventional methods for cancer therapy.

AB - New approaches to the therapy for some endocrine-dependent tumors with analogs of hypothalamic hormones are being developed on the basis of experimental studies in animal models. Analogs of luteinizing hormone-releasing hormones (LH-RH) may open new vistas for the treatment of some hormone-dependent carcinomas. It has been clearly demonstrated that both agonistic and antagonistic analogs of LH-RH can inhibit the growth of rat prostate tumors. A successful treatment of androgen-dependent prostate cancer with agonistic analogs of D-Trp6-LH-RH, D-Ser(Bu(t))6des-Gly-NH210-LH-RH ethylamide, and D-Leu6-des-Gly-NH210-LH-RH ethylamide has been documented in several hundred patients. The data accumulated so far from clinical trials suggest that LH-RH agonists can be used as an effective endocrine therapy for prostate carcinoma, thereby avoiding the side effects of estrogen and the psychologic impact of castration. Experimental animal studies and some clinical trials suggest that LH-RH agonists and/or antagonists might also be useful in the treatment of breast cancer. The results of experiments with various hypothalamic analogs in animal models of chondrosarcomas, osteosarcomas, and other tumors appear to be encouraging, but the potential clinical efficacy of LH-RH analogs in the treatment of human hormone-sensitive cancers other than breast and prostate remains to be investigated. The approach to treatment of hormone-dependent tumors based on analogs of hypothalamic hormones might become a useful addition to conventional methods for cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=0021323894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021323894&partnerID=8YFLogxK

M3 - Article

C2 - 6362868

AN - SCOPUS:0021323894

VL - 68

SP - 281

EP - 289

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 1

ER -